|Bid||19.75 x 1100|
|Ask||19.77 x 1000|
|Day's Range||18.60 - 20.67|
|52 Week Range||6.24 - 20.67|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
For Matthew Kane, the near future of life sciences is full of revolutionary possibilities – especially for new and upcoming techniques such as gene editing.
The 700+ hedge funds and famous money managers tracked by Insider Monkey have already compiled and submitted their 13F filings for the second quarter, which unveil their equity positions as of June 28. We went through these filings, fixed typos and other more significant errors and identified the changes in hedge fund portfolios. Our extensive […]
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
If you want to know who really controls Precision BioSciences, Inc. (NASDAQ:DTIL), then you'll have to look at the...
"The global economic environment is very favorable for investors. Economies are generally strong, but not too strong. Employment levels are among the strongest for many decades. Interest rates are paused at very low levels, and the risk of significant increases in the medium term seems low. Financing for transactions is freely available to good borrowers, […]
The Durham, North Carolina-based company said it had a loss of $1.99 per share. Losses, adjusted for non-recurring costs, were $1.19 per share. The genome editing company posted revenue of $5.5 million ...
Gene therapy is in vogue among biotech investors, and Precision Biosciences (DTIL), which operates in the sector, is planning an initial public offering . The Offering The company will issue 7.9 million ...
For a more comprehensive IPO calendar, check out the offering in Benzinga Cloud . IPO dates below are expected but not confirmed. Genfit S.A. (GNFT) will issue 5 million shares at $26.33 each Wednesday ...